The genetic testing company NeoGenomics has acquired Human Longevity’s oncology division, which provides next-generation sequencing services. The division of San Diego-based Human Longevity generated approximately $10 million in revenue in 2019—an amount NeoGenomics (NASDAQ: [[ticker:NEO]]) thinks it can grow by nearly 50 percent, says Charlie Eidson, investor relations and corporate development analyst, NeoGenomics. Additionally, the … Continue reading “NeoGenomics Nabs Human Longevity’s Oncology Division for $37M”
Tag: Exact Sciences
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
Lung injuries linked to electronic cigarettes have topped 800 cases, including 12 deaths, according to the Centers for Disease Control and Prevention. Public health officials aren’t sure whether the injuries are from legally sold products made by companies such as Juul, or from black-market items such as those that allow users to “vape” the active … Continue reading “Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More”
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
[Corrected 12:55 p.m. ET. See below.] Acquisitions made Pfizer what it is today: the world’s biggest drug maker measured by revenue. But as the company maps its future, CEO Albert Bourla is breaking some of that legacy apart. Blockbuster drugs such as Viagra, which was discovered in-house, and Lipitor, which came via acquisition, are currently … Continue reading “Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More”
Exact Sciences Buying Genomic Health in $2.8B Cancer Diagnostics Deal
[Updated 7/29/19, 10:19 am CT. See below.] With ambitious sales goals and its stock trading at an all-time high this year, cancer diagnostics firm Exact Sciences decided to go shopping. The result is a deal announced Monday to acquire Genomic Health for $2.8 billion in cash and stock, a combination that Exact CEO Kevin Conroy … Continue reading “Exact Sciences Buying Genomic Health in $2.8B Cancer Diagnostics Deal”
WI Watchlist: Microsoft, Exact Sciences, Shine & MKE Tech Hub
[Updated 7/3/19, 2:25 pm CT. See below.] Before everyone checks out for the Fourth of July holiday, let’s catch up on some recent Wisconsin innovation news: —Shine Medical Technologies has raised $18 million in new funding, a combination of equity and stock options, according to a filing with the SEC. The round could reach $30 … Continue reading “WI Watchlist: Microsoft, Exact Sciences, Shine & MKE Tech Hub”
WI Watchlist: Montage, LÜM, WEDC, Titan Spine, Polco, Swallow & More
A medical device for patients with swallowing disorders gets new life. A music streaming app gets an influx of cash. The state’s economic development agency faces more criticism for its practices. Startups in recruiting tech, medtech, and civic tech strike merger and acquisition deals. Read on for more details about these stories and other recent … Continue reading “WI Watchlist: Montage, LÜM, WEDC, Titan Spine, Polco, Swallow & More”
As Exact Sciences’ Sales Surge, CEO Reflects on 10-Year Turnaround
A decade ago, Kevin Conroy took the CEO job at Exact Sciences, a cancer diagnostic firm on the brink of death. Five years later, the FDA greenlit the company’s first product, Cologuard, which marked the first non-invasive, stool-based DNA screening test approved for detecting colorectal cancer. In the five years since then, Exact (NASDAQ: [[ticker:EXAS]]) … Continue reading “As Exact Sciences’ Sales Surge, CEO Reflects on 10-Year Turnaround”
Exact Sciences Eyes Cologuard Market Expansion After “Landmark Year”
[Updated 2/22/19, 2:42 pm CT. See below.] Exact Sciences screened 934,000 patients for colorectal cancer in 2018 using its stool-based diagnostic test, Cologuard, resulting in a 71 percent surge in annual revenue to $454.5 million, the company announced Thursday. Exact (NASDAQ: [[ticker:EXAS]]), which relocated from the Boston area to Madison, WI, in 2009, is one … Continue reading “Exact Sciences Eyes Cologuard Market Expansion After “Landmark Year””
WI Watchlist: Northwestern Mutual, Epic, Exact Sciences, Propeller
It’s time to catch up on notable headlines from Wisconsin’s innovation community: —Northwestern Mutual, the Milwaukee-based insurance and wealth management services giant, has hired Souheil Badran as chief innovation officer. Badran was previously president of the Americas region for Alipay, the online payments platform operated by Ant Financial, the Alibaba-owned fintech firm. Badran’s new role … Continue reading “WI Watchlist: Northwestern Mutual, Epic, Exact Sciences, Propeller”
Catalent Investing $200M to Expand in Wisconsin, Indiana
[Updated 1/8/19, 12:49 pm, with spokesperson comments.] Life sciences companies are keeping construction crews busy in Wisconsin’s state capital. The latest project comes from Somerset, NJ-based contract research and manufacturing firm Catalent (NYSE: [[ticker:CTLT]]), which said Monday it plans to invest $200 million over three years to expand its biologics manufacturing sites in Madison, WI, … Continue reading “Catalent Investing $200M to Expand in Wisconsin, Indiana”
WI Watchlist: Baird, Exact Sciences, Somna Therapeutics, & More
Happy New Year, readers. To kick off 2019, here are some recent headlines from Wisconsin’s innovation community: —The venture capital arm of Milwaukee-based Robert W. Baird & Co. is trying to raise $185 million for its fifth venture fund, according to a new SEC filing. The firm has yet to collect any of the money, … Continue reading “WI Watchlist: Baird, Exact Sciences, Somna Therapeutics, & More”
WI Watchlist: Froedtert, Gener8tor, Fujifilm Cellular Dynamics, Exact
It’s been a busy week for Wisconsin’s innovation community, with entrepreneurship events taking place statewide for Startup Wisconsin Week (check out highlights on Twitter). Here are some of the other headlines from the past week: —Wauwatosa-based Froedtert Health, which runs a network of hospitals and clinics and is affiliated with the Medical College of Wisconsin, … Continue reading “WI Watchlist: Froedtert, Gener8tor, Fujifilm Cellular Dynamics, Exact”
WI Watchlist: EatStreet, Exact Sciences, Northwestern Mutual & More
Time to catch up on some recent headlines from Wisconsin’s innovation community: —EatStreet, the Madison-based online food ordering and delivery startup, plans to expand its service to several additional Wisconsin cities and hire around 300 people in the Badger State, mostly delivery drivers, according to reports by the Wisconsin State Journal and other media outlets. … Continue reading “WI Watchlist: EatStreet, Exact Sciences, Northwestern Mutual & More”
Exact Sciences Acquires San Diego Lab Equipment Supplier Biomatrica
Exact Sciences has gone from being a customer of Biomatrica, a San Diego-based vendor of equipment for storing and preserving blood and saliva samples, to now being the company’s owner. Madison, WI-based Exact (NASDAQ: [[ticker:EXAS]]), which is developing diagnostic tests for several types of cancer, said Thursday that it has acquired Biomatrica for an undisclosed … Continue reading “Exact Sciences Acquires San Diego Lab Equipment Supplier Biomatrica”
Foxconn, Doyenne, Socialeads & More: This Week’s WI Watchlist
Madison, WI, and suburbs west of the city have received record rainfall this week, and more storms appear to be headed for the capital city this weekend. Those forecasts have created fears of further flooding and road closures downtown, which sits on an isthmus between two lakes. Your correspondent retreated to his home office after … Continue reading “Foxconn, Doyenne, Socialeads & More: This Week’s WI Watchlist”
Bio Roundup: EpiPen Shortage, Bluebird’s Bet, Biotech IPOs & More
It’s back-to-school season and that means it’s time to load up on school supplies. For many students and schools, one crucial item is in high demand but hard to come by: the EpiPen. Some schools stock the epinephrine autoinjectors so they can respond quickly to a student’s allergic reaction to food. Though the autoinjectors are … Continue reading “Bio Roundup: EpiPen Shortage, Bluebird’s Bet, Biotech IPOs & More”
Exact Sciences Shares Rise After Company Unveils Pfizer Partnership
[Updated 8/22/18 3:22 p.m. See below.] Exact Sciences has recently been ramping up its efforts to market Cologuard, the company’s flagship diagnostic test that screens patients for colorectal cancer. Since the start of 2017, Madison, WI-based Exact has brought on recording artist Harry Connick Jr. and pro golfer Jerry Kelly as spokesmen, and announced a … Continue reading “Exact Sciences Shares Rise After Company Unveils Pfizer Partnership”
Exact Sciences, Harley, Frontdesk & More: This Week’s WI Watchlist
Catch up on news from Wisconsin innovation’s community with these recent headlines: —Exact Sciences said Wednesday that it completed a lower number of its flagship diagnostic test, which screens patients for colorectal cancer, during the three-month period ended June 30 than it had projected previously. The announcement sent shares in the Madison-based company lower in … Continue reading “Exact Sciences, Harley, Frontdesk & More: This Week’s WI Watchlist”
Foxconn, Data Science, Roche & More: This Week’s Wisconsin Watchlist
The collective eyes of Wisconsin’s business and technology communities are focused on a groundbreaking ceremony that Foxconn, a Taiwan-based electronics manufacturing giant, plans to hold Thursday at the site of its future electronic display production facility in the state’s southeastern corner. President Donald Trump and other big-name politicians like House Speaker Paul Ryan and Wisconsin … Continue reading “Foxconn, Data Science, Roche & More: This Week’s Wisconsin Watchlist”
Cellular Dynamics, Rockwell, WARF & More: This Week’s WI Watchlist
Stay current on news from Wisconsin’s innovation community with these recent headlines: —Madison-based Fujifilm Cellular Dynamics said it struck an agreement with the University of California, Irvine, under which the Wisconsin company will license technology from the school in order to develop stem cell-based therapies for Alzheimer’s disease and other degenerative neurological conditions. The company, … Continue reading “Cellular Dynamics, Rockwell, WARF & More: This Week’s WI Watchlist”
Exact Sciences Seeks Up to $190M in Latest Stock Offering
Exact Sciences said Friday that it plans to raise up to $190 million through the sale of notes that can be converted into cash or shares of the company’s stock, starting in 2025. Madison, WI-based Exact (NASDAQ: [[ticker:EXAS]]) is developing several screening tests for cancer patients. Its flagship product is Cologuard, a non-invasive, stool-based DNA … Continue reading “Exact Sciences Seeks Up to $190M in Latest Stock Offering”
Exact Sciences, Mayo Clinic Share Data on DNA-Based Liver Cancer Test
Researchers at Exact Sciences and Mayo Clinic said Tuesday they have made progress toward developing a panel of blood-based DNA biomarkers that could help detect the most common form of liver cancer when the disease is still in its early stages. The two organizations said that data from a recent 244-patient study of a blood … Continue reading “Exact Sciences, Mayo Clinic Share Data on DNA-Based Liver Cancer Test”
Exact Sciences Needs New Study to Fully Benefit From ACS Change
Exact Sciences has already set plans in place to try to benefit from new guidelines from the American Cancer Society, which is lowering the recommended age at which patients should first get screened for colorectal cancer from 50 to 45. Fully realizing that objective, however, is still going to take plenty of time and money, … Continue reading “Exact Sciences Needs New Study to Fully Benefit From ACS Change”
LearnVest, SmartUQ, gBETA & More: This Week’s Wisconsin Watchlist
Keep up with news from Wisconsin’s innovation community with these recent headlines: —Northwestern Mutual said it has temporarily shut down LearnVest, a financial advisory service the Milwaukee-based life insurance giant acquired in 2015 for a reported $250 million-plus. Northwestern Mutual said LearnVest will cease providing financial planning services to consumers, and will also discontinue its … Continue reading “LearnVest, SmartUQ, gBETA & More: This Week’s Wisconsin Watchlist”
Exact Sciences CEO Conroy Talks Growth, Foxconn, Startups & More
Kevin Conroy left a law firm job in his early 30s, right after he had just made partner, to work for a venture capital-backed startup in California called Outcomes. The outcome was not what Conroy had hoped. About a year later, the business ran out of money and went bust. Even so, Conroy, now the … Continue reading “Exact Sciences CEO Conroy Talks Growth, Foxconn, Startups & More”
COO Maneesh Arora Leaving Exact Sciences; More Earnings Call Tidbits
Exact Sciences has made several additions to its leadership team in the past 18 months, but on Thursday the Madison, WI-based cancer test developer announced a key upcoming departure. Maneesh Arora, who has been Exact’s (NASDAQ: [[ticker:EXAS]]) chief operating officer since 2012, will leave the company at the end of the year, CEO and president … Continue reading “COO Maneesh Arora Leaving Exact Sciences; More Earnings Call Tidbits”
Exact Sciences Beats Quarterly Forecasts, Sending Its Stock Price Up
When leaders at Exact Sciences discussed dealing with the adversity of cold weather and a “historically severe” flu season in early 2018, some industry observers predicted a potential break in the long growth streak of the Madison, WI-based company’s flagship product, a stool-based DNA test for colorectal cancer known as Cologuard. But on Thursday, Exact … Continue reading “Exact Sciences Beats Quarterly Forecasts, Sending Its Stock Price Up”
Baird: Exact Sciences Should Rebound After First-Quarter ‘Headwinds’
Cancer screening test company Exact Sciences may not be anticipating the release of its first-quarter earnings report next week as eagerly as it has past quarters’ earnings announcements. The Madison, WI-based company in February signaled to investors that sales of its flagship product Cologuard, a stool-based DNA test for colorectal cancer screening, hit a bit … Continue reading “Baird: Exact Sciences Should Rebound After First-Quarter ‘Headwinds’”
Exact Sciences Brings on Mark Stenhouse as President of Cologuard
Mark Stenhouse will join Exact Sciences (NASDAQ: [[ticker:EXAS]]) as president of Cologuard, a stool-based screening test for colorectal cancer the Madison, WI, company has developed. Stenhouse spent nearly three decades at Lake Bluff, IL-based Abbott Laboratories (NYSE: [[ticker:ABT]]) and AbbVie (NYSE: [[ticker:ABBV]]), a pharmaceuticals-focused spinout of Abbott Laboratories launched in 2013. Most recently, Stenhouse was … Continue reading “Exact Sciences Brings on Mark Stenhouse as President of Cologuard”
Exact Sciences: Harry Connick Jr., Wife to Lead New Cancer Campaign
[Updated 3/19/18 5:06 p.m. See below.] Two months after Exact Sciences said it planned to introduce a new celebrity spokesperson to plug its stool-based screening test for colorectal cancer, the company has pulled back the curtain on who it will be. The recording artist and entertainer Harry Connick Jr. will attempt to raise awareness about … Continue reading “Exact Sciences: Harry Connick Jr., Wife to Lead New Cancer Campaign”
Exact Sciences: Severe Flu Season Slows Down Cancer Test’s Sales
Exact Sciences says two staples of winter—cold weather and flu season—have led patients and doctors to cancel more medical appointments than usual in recent months. As a result, the growth of Cologuard, Exact’s stool-based DNA test for colorectal cancer screening, has slowed, the Madison, WI-based company said. Exact (NASDAQ: [[ticker:EXAS]]), which is developing screening tests … Continue reading “Exact Sciences: Severe Flu Season Slows Down Cancer Test’s Sales”
Exact Sciences Shares Fall, Despite Better-Than-Expected P&L Results
Exact Sciences reported quarterly profit-and-loss results Thursday that beat many analysts’ estimates. However, investors did not on the whole appear to be impressed, sending the company’s stock price more than 6 percent lower in after-hours trading. Madison, WI-based Exact (NASDAQ: [[ticker:EXAS]]), is developing screening tests for a variety of cancers. Its flagship product is Cologuard, … Continue reading “Exact Sciences Shares Fall, Despite Better-Than-Expected P&L Results”
Exact Targets Large Hospital Systems to Boost Sales of Cancer Test
Exact Sciences is setting its sights on large hospital systems across the country as part of an effort to get more doctors to order Cologuard, Exact’s stool-based DNA test for colorectal cancer screening, for their patients. Madison, WI-based Exact (NASDAQ: [[ticker:EXAS]]) launched Cologuard in 2014 and as of last month, nearly 102,000 clinicians in the … Continue reading “Exact Targets Large Hospital Systems to Boost Sales of Cancer Test”
Exact Sciences, Generic Drugs, WEDC & More: This Week’s WI Watchlist
Catch up on news from Wisconsin’s innovation community with these recent headlines: —Citron Research published its second report in the past 12 months arguing that prospective investors should think twice before buying stock in Madison-based Exact Sciences (NASDAQ: [[ticker:EXAS]]). The company’s flagship product is a non-invasive, stool-based DNA test for colorectal cancer called Cologuard. In … Continue reading “Exact Sciences, Generic Drugs, WEDC & More: This Week’s WI Watchlist”
Armune Bio’s Cancer Detection Tech Finds New Home with Exact Sciences
The annual J.P. Morgan Healthcare Conference, held earlier this month in San Francisco, is a popular venue for biotech companies to announce new deals and milestones achieved. One such announcement from this year’s event has largely flown under the radar: Madison, WI-based molecular diagnostics company Exact Sciences acquired Armune BioScience, a cancer diagnostic startup with … Continue reading “Armune Bio’s Cancer Detection Tech Finds New Home with Exact Sciences”
Exact, Spectrum, PerBlue, & More: This Week’s Wisconsin Watchlist
It was a newsy week for Wisconsin’s innovation community. Catch up on some of the major happenings with these recent headlines: —Exact Sciences’ (NASDAQ: [[ticker:EXAS]]) stock price finished the trading day on Wednesday down nearly 10 percent after the American Society of Clinical Oncology (ASCO) published the results of a study evaluating a liquid biopsy … Continue reading “Exact, Spectrum, PerBlue, & More: This Week’s Wisconsin Watchlist”
Exact Sciences, Shine, Redox & More: This Week’s Wisconsin Watchlist
Keep up with the latest news from Wisconsin’s innovation community with these recent headlines: —Exact Sciences said it plans to raise up to $600 million through the sale of notes that can be converted into cash or shares of the company’s common stock, starting in 2025. Madison-based Exact (NASDAQ: [[ticker:EXAS]]) is developing several screening tests … Continue reading “Exact Sciences, Shine, Redox & More: This Week’s Wisconsin Watchlist”
Exact Looks to Sales Force, Ads to Boost Cancer Test Sales in 2018
Exact Sciences plans to expand its sales force by 200 employees, ramp up its digital and social media marketing campaigns, and introduce a new “national celebrity spokesperson” this year, as the company seeks to increase sales of its flagship product, a stool-based DNA test for colorectal cancer. Madison, WI-based Exact (NASDAQ: [[ticker:EXAS]]) detailed some of … Continue reading “Exact Looks to Sales Force, Ads to Boost Cancer Test Sales in 2018”
Stonehouse, AkitaBox, Iverson, & More: This Week’s WI Watchlist
Stay current on the latest news from Wisconsin’s innovation community with these recent headlines: —Stonehouse Water Technologies, a Milwaukee-based startup developing energy-efficient water purification systems, said it raised more than $1.5 million from investors. Launched in 2012, Stonehouse is developing a water purifier about the size of a dehumidifier that’s designed for use in residential, … Continue reading “Stonehouse, AkitaBox, Iverson, & More: This Week’s WI Watchlist”
CFO: Exact in ‘Investment Mode,’ Seeks to Advance New Cancer Tests
Shares in Exact Sciences have more than quadrupled in 2017, and the stock’s impressive run has led some analysts to question whether it’s a smart buy at the current price. But Jeff Elliott, Exact’s chief financial officer, says he believes his company is poised for continued growth as it adds laboratory space and works to … Continue reading “CFO: Exact in ‘Investment Mode,’ Seeks to Advance New Cancer Tests”
Foxconn, Exact, Ludois, & More: This Week’s Wisconsin Watchlist
A major deal between Wisconsin legislators and a foreign electronics assembler, a biotech company’s expansion plans, and an award for electric motors research are among these recent headlines from the state’s innovation community: —The state of Wisconsin and Foxconn, an electronics assembler and technology development business based in Taiwan, signed off on a deal that … Continue reading “Foxconn, Exact, Ludois, & More: This Week’s Wisconsin Watchlist”
Rockwell, Sift, Fund of Funds, & More: This Week’s WI Watchlist
Catch up on the latest news from Wisconsin’s innovation community with these recent headlines: —Milwaukee-based Rockwell Automation (NYSE: [[ticker:ROK]]) declined two takeover offers made by Emerson Electric (NYSE: [[ticker:EMR]]) in the past three months, including one in October that valued Rockwell at more than $27 billion, CNBC reported. Rockwell develops software and provides services for … Continue reading “Rockwell, Sift, Fund of Funds, & More: This Week’s WI Watchlist”
Exact Sciences Plots Expansion Strategy as Cancer Test Sales Boom
Exact Sciences posted its fourth consecutive strong quarter—beating analysts’ and the company’s own projections of financial and business performance—and investors reacted favorably. Madison, WI-based Exact (NASDAQ: [[ticker:EXAS]]) develops diagnostic tests for several types of cancer. Its flagship product is Cologuard, a stool-based DNA test for colorectal cancer. Exact said it completed about 161,000 of the … Continue reading “Exact Sciences Plots Expansion Strategy as Cancer Test Sales Boom”
Gregor Joins Texas Accelerator to Advance Prostate Cancer Test
When Tobias Zutz left his job as a senior research associate at Exact Sciences in 2015, he knew he wanted his next career stop to be at a smaller organization. Zutz worked at Madison, WI-based Exact (NASDAQ: [[ticker:EXAS]]), which has commercialized a stool-based DNA test for colorectal cancer, for more than five years. During his … Continue reading “Gregor Joins Texas Accelerator to Advance Prostate Cancer Test”
CDI, Novascan, WID, 4490, & More: This Week’s Wisconsin Watchlist
Coverage and analysis of Taiwan-based Foxconn’s announcement that it will invest $10 billion to build an electronic display-making plant in Wisconsin has dominated business news around the state lately. However, there have also been numerous notable happenings apart from the Foxconn saga. Let’s catch up on some of them: —Cellular Dynamics International scrapped plans to … Continue reading “CDI, Novascan, WID, 4490, & More: This Week’s Wisconsin Watchlist”
Exact Sciences Again Boosts Sales Projections for Flagship Product
Exact Sciences continues to raise the bar. Strong sales for Exact’s (NASDAQ: [[ticker:EXAS]]) flagship product, the colorectal cancer test Cologuard, led the Madison, WI-based company to boost its 2017 revenue forecast to between $230 million and $240 million. That marks the second consecutive quarter that the company has increased sales projections for its stool-based DNA … Continue reading “Exact Sciences Again Boosts Sales Projections for Flagship Product”
Exact, Microscopy, FairSquare, & More: This Week’s WI Watchlist
Keep up with the latest news from Wisconsin’s innovation community with these recent headlines: —Exact Sciences is evaluating two potential sites where it would house a second lab for processing results of its flagship product Cologuard, a stool-based DNA test for colorectal cancer, the Wisconsin State Journal reported. Madison-based Exact (NASDAQ: [[ticker:EXAS]]) said it completed … Continue reading “Exact, Microscopy, FairSquare, & More: This Week’s WI Watchlist”
Exact, WARF, Murfie, Microbes, & More: This Week’s WI Watchlist
Keep up with the latest news from Wisconsin’s innovation community with these recent headlines. —Madison-based Exact Sciences (NASDAQ: [[ticker:EXAS]]), whose flagship product is a stool-based screening test for colorectal cancer, issued a recall of 15 pieces of equipment used to mix stool samples in preparation for testing at the company’s lab. According to the FDA, … Continue reading “Exact, WARF, Murfie, Microbes, & More: This Week’s WI Watchlist”
Exact Sciences To Sell 7 to 8 Million Shares in Stock Offering
Exact Sciences today announced that it is selling 7 million shares of common stock at $35 per share, a 4.5 discount off of Tuesday’s closing price. The offering is underwritten by Bank of America Merrill Lynch, Jefferies, and Robert W. Baird & Co., which have the option to purchase up to 1.05 million additional shares. … Continue reading “Exact Sciences To Sell 7 to 8 Million Shares in Stock Offering”
Shares in Exact Sciences Rise on UnitedHealthcare Coverage Decision
Exact Sciences saw its stock price rise late Tuesday on news that the health insurer UnitedHealthcare will cover Cologuard, Exact’s stool-based DNA test for colorectal cancer, starting July 1. Shares in Madison, WI-based Exact (NASDAQ: [[ticker:EXAS]]) were trading at $35.30 apiece as of 7:47 p.m. in New York, up more than 8.1 percent from Tuesday’s … Continue reading “Shares in Exact Sciences Rise on UnitedHealthcare Coverage Decision”